Librela

Canine osteoarthritis (OA) is both a common and chronic condition that many dogs are diagnosed with. Librela is a monoclonal antibody. Librela is the first and only monthly injectable monoclonal antibody therapy for dogs with osteoarthritis (OA) pain. Librela works as a potent inhibitor of canine NGF activity, a key OA pain mediator, thus reducing canine OA pain.

Librela is:

Approved as safe and effective and provides long-term canine OA pain control
A monthly subcutaneous injection, administered at the clinic by veterinary professionals
Reduced canine OA pain, which led to increased activity and improved quality of life

for more information visit:  https://www.zoetisus.com/products/dogs/librela-a-new-era-in-treatment